Food and drug administration approved adjuvant cemiplimab (libtayo) for adults with cutaneous squamous cell carcinoma who are at a high risk for recurrence after surgery and radiation. Fda label information for this drug is available at dailymed Basal cell carcinoma (bcc) (a type of skin cancer). The fda evaluated libtayo under priority review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions. Cemiplimab is a newer cancer treatment that has brought hope to patients with advanced skin and lung cancers It is part of an exciting group of drugs called immune checkpoint inhibitors, which help the body’s immune system fight cancer more effectively
Cemiplimab is approved by the u.s Food and drug administration (fda) to treat advanced forms of skin cancers, including cutaneous squamous. Libtayo will be a game changer for head and neck squamous cell cancer Fda approved in mid october
OPEN
